Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910098 | 0.99 | STAT3 (0.39) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL5133634 | 0.96 | STAT3 (0.42) | STAT3STAT1MAPTHTTSIRT1 | |
| SCHEMBL4551743 | 0.96 | STAT3 (0.44) | STAT3STAT1MAPTHTTSIRT1 | |
| SCHEMBL3720959 | 0.95 | STAT3 (0.37) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL6003904 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL3522373 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL3520094 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL15510967 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL7647119 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL17419215 | 0.95 | STAT3 (0.43) | STAT3STAT1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257500-A1 | RADICALLY POLYMERIZABLE COMPOSITIONS | BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) | 2023-08-17 | — | — | US | disclosed |
| US-11518834-B2 | Radically polymerizable compositions | Polynt Composites USA, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3906265-A1 | RADICALLY POLYMERIZABLE COMPOSITIONS | Polynt Composites USA Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113474383-A | Radically polymerizable composition | 波林复合材料美国股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020142632-A1 | RADICALLY POLYMERIZABLE COMPOSITIONS | Polynt Composites USA, Inc. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200207895-A1 | RADICALLY POLYMERIZABLE COMPOSITIONS | BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10696863-B2 | Additives for curable liquid compositions | DURA CHEMICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180291233-A1 | Additives for Curable Liquid Compositions | DURA CHEMICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20180265470-A1 | Drier Composition and Use Thereof | PPG EUROPE B V (NL) | 2018-09-20 | — | — | US | disclosed |
| US-9976054-B2 | Additives for curable liquid compositions | DURA CHEMICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2012092034-A2 | ADDITIVES FOR CURABLE LIQUID COMPOSITIONS | DURA CHEMICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165435-A1 | ADDITIVES FOR CURABLE LIQUID COMPOSITIONS | DURA CHEMICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20080119504-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | AXON BIOCHEMICALS B.V. (NL) | 2008-05-22 | — | — | US | disclosed |
| US-7332503-B2 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2008-02-19 | — | — | US | disclosed |
| US-7238705-B2 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2007-07-03 | — | — | US | disclosed |
| US-20050143408-A1 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2005-06-30 | — | — | US | disclosed |
| US-20040018956-A1 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2004-01-29 | — | — | US | disclosed |
| EP-1309553-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | Axon Biochemicals B.V. (NL) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014279-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | AXON BIOCHEMICALS B.V. (NL) | 2002-02-21 | — | — | WO | disclosed |
| WO-1995029914-A1 | A METHOD OF SYNTHESIZING 5,15-DIARYLBENZOCHLORIN-7-ONE COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143408-A1 | Aporphine esters and their use in therapy | PRLHR, LPXN, NPSR1 | STAT3 3999/4885STAT1 3802/4885MAPT 1857/4885 |
| US-20180265470-A1 | Drier Composition and Use Thereof | DCTD, AP3D1, TET2 | STAT3 4191/4885STAT1 4549/4885MAPT 1001/4885 |
| US-20040018956-A1 | Aporphine esters and their use in therapy | PRLHR, LPXN, NPSR1 | STAT3 3999/4885STAT1 3802/4885MAPT 1857/4885 |
| US-20080119504-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | PRLHR, LPXN, HTR1A | STAT3 4158/4885STAT1 3938/4885MAPT 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.